Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 19Active not recruiting 10Completed 8Terminated 2Not yet recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Metastatic Castration Resistant Prostate Cancer 1

Interventions

Docetaxel 56Prednisone 36enzalutamide 25Leuprolide 24Magnetic Resonance Spectroscopy 19Abiraterone Acetate 19bicalutamide 17Radiotherapy 15Goserelin 15abiraterone 12acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11olaparib 9Androgen Antagonists 9gallium 68 PSMA-11 8cabazitaxel 8Radiotherapy, Intensity-Modulated 8Metformin 8Ketoconazole 8Gonadotropin-Releasing Hormone 8Cyclophosphamide 8apalutamide 7Doxorubicin 7luprolide acetate gel depot 6cabozantinib 6Radiosurgery 6Estramustine 6Dexamethasone 6Calcitriol 6Biopsy 6pembrolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Prostatic Neoplasms × Pluvicto × Clear all
NCT06516510 2025-09-25

A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer

Blue Earth Therapeutics Ltd

Phase EARLY_PHASE1 Terminated
17 enrolled
Genitourinary

Prostatic Neoplasms

NCT03545165 2021-08-24

177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC

Weill Medical College of Cornell University

Phase 1/2 Terminated
6 enrolled 24 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡